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Robert W Snow1,2Abstract
Controversy surrounds the precise numbers of malaria deaths and clinical episodes in Africa. This would not have
surprised malariologists working in Africa 60 years ago as they began to unravel the enigma that is ‘malaria’. Malaria
is a complex disease manifesting as a multitude of symptoms, degrees of severity and indirect morbid consequences.
Clinical immunity develops quickly and the presence of infection cannot always be used to distinguish between
malaria and other illnesses. During the 1950s and 1960s parasite prevalence was used in preference to statistics on
malaria mortality and morbidity. An argument is made for a resurrection of this measure of the quantity of malaria
across Africa as a more reliable means to understand the impact of control.
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During a visit to Uganda and Kenya in 1929, SP James
wrote ‘… there is, as yet, little or no knowledge even of the
symptoms and effects of the chronic infestations with mal-
aria parasites from which many native children and adults
suffer, to say nothing of the wide gaps in knowledge of [sic]
regarding the distribution, relative incidence and seasonal
prevalence of different species of the malaria parasite’ [1].
Over the next 30 years, epidemiological studies im-
proved our basic understanding of the clinical impact of
malaria infection among communities living under stable,
endemic settings in Nigeria [2-4], Liberia [5], Ghana [6,7],
the Belgian Congo [8,9], Kenya [10,11] and Tanzania
[12,13]. All these studies identified the power and rapidity
of natural, repeat parasite exposure on the development of
clinical immunity, the resultant absence of disease in
adults and how immunity confounded any reliable estima-
tions of the clinical burden posed by infection in rural
communities in Africa.
In his comprehensive treatise on malaria, WF Boyd
stated that ‘…there is little value to reports received from
physicians .... malaria morbidity reporting, even where
malaria is classed as a reportable disease, is notoriouslyCorrespondence: rsnow@kemri-wellcome.org
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known to us personally, is it sufficiently complete to be
put to epidemiological use’ [14]. According to those writ-
ing on their experiences, the consensus was that ‘There
is little doubt that the diagnosis of malaria in the im-
mune or semi-immune African is subject as often as not
to individual interpretation of clinical symptoms by the
medical officer...... to complicate the issue, a positive
blood-slide from the indigenous inhabitant of West Africa
is not necessarily a criterion of the diagnosis’ [4].
Nevertheless, there was pressure to articulate the mal-
aria burden in Africa as part of the World Health Organi-
zation’s Global Malaria Eradication Programme (GMEP).
A review of autopsy findings in Lagos performed on 3,085
children younger than 15-years old between 1933 and
1948 [4], formed the basis upon which it was estimated
that 5% of children born in Africa would die before their
fifth birthday from malaria and, by extrapolation, led to
approximately 1 million malaria deaths every year. The
‘million malaria deaths’ became an accepted prelude to
any report on malaria in Africa for decades.Renewed interest in clinical epidemiology of malaria and
new numbers: 1990s
It took another forty years before an interest in the clin-
ical epidemiology of Plasmodium falciparum, the most
significant malaria parasite transmitted in Africa in
terms of disease burden, was to re-emerge [15]. Studiesis is an Open Access article distributed under the terms of the Creative
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based detection of the phenotypes of severe malaria and
community-based mortality surveillance increased across
Africa generating a wealth of new information. New bur-
den estimates began to emerge based on replications of
single studies such as those done by Bruce-Chwatt in the
1950s [16,17].
Toward the end of the 1990s, Africa was in the grips
of a malaria epidemic [18]. The need to raise the profile
of malaria in Africa, as part of advocacy for an increase
in financing for the nascent Roll Back Malaria initiative
[19], demanded new numbers. At the same time novel
approaches to estimating global cause-specific mortality
and disability burdens were gaining credibility for setting
international health priorities [20]. In 1999, combina-
tions of data were used to provide a new estimate of the
malaria mortality burden in Africa based on assemblies
of survey data on clinical attack rates and verbal autopsy
or confirmed malaria death rates [21]. This analysis esti-
mated there were more than 221 million febrile clinical
events due to P. falciparum. Approximately one million
deaths were directly attributable to malaria in 1995 [21],
a similar finding to that of Bruce-Chwatt’s nearly 50 years
earlier. Since then adaptations of this approach have
been championed by many (including the author), provid-
ing new, refined numbers through increasingly complex
models and marginal increases in empirical epidemio-
logical data [22-41].
Generating new numbers is at risk of becoming an in-
dustry, no longer informed by adequate biological, clin-
ical and public health reflection or need. Do we really
know how many clinical events or deaths are due to P.
falciparum in Africa? More importantly, are we measur-
ing a quantity that is malaria morbidity and mortality?
Why is it so difficult to measure the malaria burden
in Africa?
Even with comparatively sophisticated surveillance, mor-
bid and fatal events due to malaria in Africa are often
treated outside formal health systems and cause of death
largely unverifiable. Malaria is a complex disease mani-
festing as a multitude of symptoms, degrees of severity,
with indirect morbid consequences. Without extensive
laboratory testing, most symptoms of malaria are indis-
tinguishable from other major causes of morbidity and
mortality in young children. Clinical immunity develops
quickly during early childhood following repeated para-
site exposure, yet how many new infection encounters
result in premunition against disease and why some chil-
dren die and others survive remains unclear [15]. Be-
cause immunity develops throughout childhood, the
presence of infection cannot always be used to distin-
guish between malaria and other illnesses sharing similar
presenting symptoms.Recent disease burden estimations have focused almost
entirely on direct (those due to the defined clinical syn-
dromes of malaria) measures of morbidity and mortality.
For mortality the survey approaches assume that one can
use a history from a bereaved relative, a verbal autopsy, to
unambiguously assign a death to a single cause, malaria.
This is a challenge for even the most experienced clini-
cians with a severely ill patient in front of them and sup-
ported by the best possible laboratory and diagnostic
services. Not surprisingly, comparisons of verbal autopsy
diagnoses made weeks or months after a child had died of
confirmed malaria in hospital have all shown poor sensi-
tivity across Africa [42]. Some have argued that, despite all
its limitations, the verbal autopsy is the best tool we cur-
rently have [43], but it may be too blunt to provide any re-
liable data on deaths that are an immediate consequence
of a single malaria episode.
Epidemiological models of morbidity do not recognize
the intrinsic difficulties of measuring these events. Case
definitions change with age and with endemicity [44-50],
passive versus active case detection provides very differ-
ent clinical endpoints [51] and repeat weekly examina-
tions of the same individual alter the ‘natural’ incidence
of disease [52]. Standardized clinical endpoints during
randomized control trials of new interventions provide
important efficacy data, but do not reflect a natural dis-
ease burden within trial sites or between sites across dif-
ferent transmission conditions in Africa.
Theory suggests that the association between malaria
mortality and transmission intensity is non-linear [53];
the few data available on severe, life-threatening disease
support the position of a non-linear association with
transmission intensity that saturates at moderate levels
of repeat parasite exposure [54,55]. In reality, without
better measures of disease outcome, the precise relation-
ship between mortality and malaria transmission re-
mains unknown [56].
As part of recent efforts to define the P. falciparum
global burden 25 estimates of epidemiologically mea-
sured incidence from 16 locations between 1993 and
2001 were used to interpolate risks across the African
continent [30]; for mortality, results from 110 verbal aut-
opsy studies from 64 locations and 11 ‘national’ studies
in nine African countries were used to provide estimates
by year by country between 1980 and 2013 [37,41]. The
paucity of empirical disease data in time and across the
vast space occupied by diverse epidemiological, social and
health system conditions is striking, providing a constant
barrier to the generalizability of this approach to burden
estimation.
Providing modelled uncertainty around point estimates
of morbidity and mortality aims to provide statistical legit-
imacy for the interpolated burden numbers. The width of
the confidence intervals either side of the median point
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estimate. Inevitably, the confidence intervals overlap be-
tween different modelled estimates, leading some to argue
that newer modelling approaches are as ‘good’ as older
modelling approaches [57]. A more honest interpretation
is that we cannot be statistically confident in any modelled
estimate of malaria morbidity or mortality in Africa.
There continues to be a failure to triangulate model
predictions with other information on disease burden in
Africa. The most recent malaria incidence and mortality
models propose that there were more than 19,000 mal-
aria cases and 164 malaria deaths in 2013 in Swaziland
[41]. During a national sample survey of infection in
2010 only two infections (one P. falciparum and one P.
malariae) were identified by polymerase chain reaction
[58]; malaria is a notifiable disease and case investiga-
tions of 779 malaria events showed that only 404 cases
over three years (2010 to 2012) were a result of locally
acquired infections [59]. The Rwandan government, aim-
ing for elimination, might be equally surprised by the esti-
mated 3,569 deaths directly attributed to P. falciparum in
2013 [41]. These examples highlight a more general point:
we need to evolve a culture of careful multiple data inves-
tigation, triangulation and interrogation as a check on
modelling approaches to disease burden at global scales.
Indirect effects of parasitization
The standard global disease burden approach assumes
that one child dies from one disease [20]; as such, sig-
nificant indirect consequences of malaria infection are
ignored. The consequences of reducing malaria parasite
exposure on non-malaria mortality have been described
during aggressive vector control across Africa. At Pare-
Taveta, on the Kenyan-Tanzanian border, three years of
house spraying reduced parasite rates from 60% to 5%
and was associated with a halving of infant and under-
five mortality that reverted to pre-intervention levels
after spraying ceased [60,61]. Indoor house spraying with
residual insecticides in a high transmission area of Kenya
resulted in an almost immediate 96% reduction in para-
site exposure that led within three years to a 44% reduc-
tion in crude death rates among all age groups and a
40% reduction in infant mortality [62]. Recently, eight
rounds of house-spraying and distribution of insecticide
treated nets on the island of Bioko, Equatorial Guinea,
between 2004 and 2008 resulted in 95% effective cover-
age of children younger than five-years old, reduced in-
fection prevalence from 42% to 18% and resulted in a
reduction in under-five all-cause mortality from 157 to
55 per 1,000 live births [63].
The immediacy of the impact, the effect size and evi-
dence of rebound following cessation of control, all sug-
gest that the reductions seen in overall mortality must
be explained by the reductions in parasite exposure andthat these reductions are greater than can be explained
through a reduction in malaria-specific mortality alone.
The indirect consequences of malaria infection may be
mediated through a number of mechanisms [64]. These
include the insidious effects of chronic or repeated infec-
tion that lead to increased risks of severe anemia in preg-
nant women and children, growth retardation of fetuses
and low-birth weight newborns [27,65,66]. There is also
compelling evidence of the role played by P. falciparum
infection in increasing the risks of invasive bacterial dis-
ease, most notably non-typhoidal Salmonellae [67-69].
When malaria transmission dramatically declined over ten
years on the Kenyan coast the incidence of life-threatening
gram-negative bacteremia was halved [70], confirming that
this was directly related to malaria transmission. Further,
there appears to be a protective effect of sickle cell trait
against invasive bacterial disease, of the same order as its
protection against malaria [70].
What can we measure?
The indirect impact of malaria infection may exceed any
direct mortality outcomes, even if the latter could be
measured. All-cause mortality is a definable endpoint
and it has been argued that one should view malaria in-
fection as a risk factor for survival, in similar ways to
how under nutrition is treated as a risk [71]. This is im-
portant because it leads us onto what malaria quantity
can be measured.
The complex direct and indirect public health burden
posed by malaria in Africa is predominantly caused by a
single pathogen, P. falciparum. Other high burden dis-
eases are usually measured from routine survey data on
the prevalence and incidence of the pathogen. Unlike
HIV, the direct relationship between malaria infection
and disease outcomes is complicated by genetically regu-
lated, naturally acquired exposure-dependent immunity
and less well understood variations in parasite virulence.
As with all diagnostics for most pathogens, there are
margins of error in being able to detect malaria parasites
in the peripheral blood of infected hosts [72]. But infec-
tion can be measured with a much higher degree of cer-
tainty, more rapidly and more ubiquitously than the
symptomatic consequences of infection based on a con-
stellation of common childhood symptoms.
In Boyd’s manual on malariology it states that ‘It is inex-
cusable to initiate control activities in any community
without a prior survey to determine … the endemic level
at which malaria is prevailing, and the extent of its
localization… ‘ [13]. During the GMEP era the prevalence
of the malaria parasite in a community was viewed as a re-
liable index of risk that would define how interventions
were spatially targeted, and progress measured [73-75].
National surveys were undertaken in thousands of villages
across Africa as part of ‘pre-eradication’ reconnaissance.
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dence’ among infants born during periods of interven-
tion was used to measure the immediacy of control
impact [76].
There has been a renaissance in measuring infection
prevalence during national sample household malaria indi-
cator surveys since 2005. These more recent national
surveys are poor substitutes for those designed and under-
taken during the 1950s and 1960s. Current national mal-
aria parasite prevalence surveys often cover fewer than 20
children younger than five years of age per sampled cluster
and rarely consider infection prevalence among the entire
community or provide information on multiple parasite or
life-cycle stages of detected infections. Nevertheless, when
combined with other available survey data, notably the re-
vival of school-based measures of malaria risk [77], these
data provide a unique opportunity to interpolate infection
risks across space and time. The ubiquity and comparative
sensitivity of parasite prevalence as a metric of risk has
made it possible, for the first time, to measure changes in
parasite exposure across Africa based on 26,746 surveys at
21,341 locations [78].
It has long been recognized that when transmission
becomes less intense and unstable, there is a closer associ-
ation between infection prevalence and disease. Disease is
theoretically easier to measure without the confounding
influence of immunity [79]. Conversely, under conditions
of regular parasite exposure disease is much harder to de-
fine and the amount of malaria in a community is better
measured by the prevalence of the parasite during a cross-
sectional survey [79]. The level of transmission one needs
to consider when measuring disease or infection is not
clear [80]; however, if one assumes that when prevalence
is more than 5% disease is hard to measure, then this cur-
rently covers 519 million people living in 41 countries of
sub-Saharan Africa [78].
Conclusions
Are we any less ignorant of malaria’s role in the health
of communities in Africa since SP James visited East
Africa in 1929? We know much more now on the pro-
tective role of acquired immunity, the clinical presenta-
tions and pathology of malaria as a disease, how disease
phenotypes and age-patterns vary according to the in-
tensity of transmission, the diversity of parasite exposure
across the continent and the indirect consequences of
malaria infection on health.
Multilateral agencies continue to demand actual num-
bers of a disease intrinsically hard to define, tending to
focus on the point median estimates and ignoring the
confidence interval. People often argue that some num-
bers are better than none. Sixty years ago this was prob-
ably a fair position; 15 to 20 years ago this might have
been legitimate at a time when a case needed to be madeto highlight the 40 year neglect of malaria and its threat
to global development. At the launch of the GMEP and
the more recent Roll Back Malaria (RBM) initiatives,
numbers have been useful advocacy tools.
In the absence of reliable civil and health registration
systems across a large part of stable endemic sub-
Saharan Africa there are two things we can measure:
whether someone has died (Millennium Development
Goal 4) and whether someone is infected with the mal-
aria parasite (not included in any development goals).
The former encompasses the complex array of all risks
posed by infection with malaria parasites; the latter is
the etiological risk factor for premature mortality. Both
are measurable with an acceptable degree of certainty.
Yet it remains impossible to provide a single figure of
the number of deaths or clinical events resulting from P.
falciparum infection; or more importantly, how many of
these events have been averted since the launch of unpre-
cedented overseas development assistance since 2000.
It is a tragedy that, despite billions of health dollars
spent on the control of malaria in Africa since 2000, we
remain so uncertain about the health impact of this
funding in 2014. Among countries at the margins of
stable transmission in Africa, malaria elimination is now
viewed, once again, as possible. In these areas, most in-
fections will lead to an important disease outcome un-
affected by acquired immunity and countries will require
a sophisticated system of disease surveillance to track
progress toward the ambitious target of no new clinical
events. However, the majority of Africa’s public health
burden caused by P. falciparum does not occur at the
margins but in the middle belt of sub-Saharan Africa
where intense transmission leads to immunity within the
first few years of life and the unique distinction of a mal-
aria disease event is much harder to define. Investing
now in longitudinal, more traditional, epidemiological
metrics of malaria including species-specific infection
prevalence, mosquito vector species abundance, bionom-
ics and infectivity, accompanied by carefully assembled,
quality assured clinical data from hospitals will provide
public health specialists an opportunity to examine the
success of continued investment in current control tools.
Relying upon models based on inadequate, incomplete
data of poorly defined disease outcomes should no lon-
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